A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects W/ Essential Thromboythemia Who Are Resistant to or Intolerant of
Administered By
Awarded By
Contributors
- Arcasoy, Murat Osman Principal Investigator
Start/End
- June 15, 2017 - March 18, 2020